Encompass Health EHC
- Market cap
- $12.2B
- PE
- 20.2×
- 10y median 18.4×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.0×
- EV/EBIT
- 13.7×
- Revenue, 12 months
- $6.2B
- +9% on a year ago
- Net margin
- 10.0%
- Free cash flow yield
- 3.4%
Encompass Health trades at 20.2× trailing earnings, near its ten-year median. Revenue was $6.2B over the last twelve months, up 9% on a year earlier with a 10% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.2B+11% | $1.2B+10% | $1.3B+13% | $1.3B+10% | $1.4B+12% | $1.4B+13% | $1.5B+11% | $1.5B+12% | $1.5B+9% | $1.5B+10% | $1.6B+9% | $1.6B+10% | |
| SG&A | $49.8M+31% | $53.1M+24% | $50.2M+16% | $50.5M−9% | $54M+8% | $54.5M+3% | $52.3M+4% | $59.4M+18% | $56.1M+4% | $68.4M+26% | $58.2M+11% | $62.6M+5% |
| $179.4M+21% | $189.9M+6% | $207.5M+16% | $215.6M+17% | $209.1M+17% | $232.3M+22% | $267M+29% | $259.1M+20% | $243.6M+17% | $283.4M+22% | $301.6M+13% | $288.4M+11% | |
| Interest expense | $35.9M−6% | $34.9M−7% | $35.2M−3% | $34.3M−6% | $34.9M−3% | $33M−5% | $31.8M−10% | $30.4M−11% | $30.8M−12% | $30.2M−9% | $31.8M+0% | $32.8M+8% |
| Pre-tax income | $145M+35% | $164.8M+9% | $178.4M+22% | $186M+23% | $183.8M+27% | $201.4M+22% | $238.6M+34% | $236.8M+27% | $219.9M+20% | $257.7M+28% | $288.7M+21% | $261.6M+11% |
| $30.3M+39% | $37.2M+17% | $38.3M+20% | $38.3M+17% | $36M+19% | $37.6M+1% | $41.6M+9% | $51M+33% | $44.9M+25% | $55.4M+47% | $56.4M+36% | $53.6M+5% | |
| Net income | $85.3M+88% | $87.6M−2% | $112.5M+28% | $114.1M+25% | $108.2M+27% | $120.9M+38% | $151.5M+35% | $142.1M+25% | $126.5M+17% | $146.1M+21% | $194.5M+28% | $153.9M+8% |
| $0.84+87% | $0.85−5% | $1.10+26% | $1.12+24% | $1.06+26% | $1.18+39% | $1.48+35% | $1.39+24% | $1.24+17% | $1.43+21% | $1.93+30% | $1.54+11% | |
| 101.4M+1% | 101.9M+1% | 102.2M+1% | 102M+1% | 102.1M+1% | 102.2M+0% | 102.1M−0% | 102.3M+0% | 102.3M+0% | 101.9M−0% | 100.6M−2% | 100M−2% |
Operating income: 42 periods, Q2 FY09 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q2 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY09 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY13: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Encompass Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EHCEncompass Health | $12.2B | 20.2× | 18.4× | n/m | 2.0× | +9% | 10.0% |
| BTSGBrightSpring Health Services | $11.9B | 36.4× | 57.7× | n/m | 0.8× | +26% | 2.5% |
| DVADavita | $11.7B | 15.0× | 16.1× | n/m | 0.8× | +6% | 6.0% |
| UHSUniversal Health Services | $11B | 7.6× | 13.6× | n/m | 0.6× | +10% | 8.4% |
| ENSGEnsign | $10.2B | 27.5× | 25.5× | n/m | 1.9× | +19% | 6.9% |
| PACSPACS | $7.5B | 27.2× | 27.2× | n/m | 1.4× | +15% | 4.8% |
| THCTenet Healthcare | $21.6B | 10.4× | 11.2× | 12.9× | 1.0× | +5% | 10.3% |
| CHEChemed | $6.7B | 25.8× | 29.0× | n/m | 2.6× | +3% | 10.6% |
| SHCSotera Health | $5.2B | 31.8× | 55.4× | n/m | 4.2× | +8% | 13.4% |
| CONConcentra Group Holdings Parent | $5B | 25.5× | 17.5× | n/m | 2.2× | +14% | 8.7% |
| LFSTLifeStance Health | $4.9B | 99.5× | 142× | n/m | 3.1× | +20% | 3.2% |
| Peer median | $8.9B | 26.5× | 26.3× | 12.9× | 1.6× | +12% | 7.7% |
Investors who own it
Investors we follow who held Encompass Health at the end of Jun 30, 2026, from their 13F filings.
- Reinhart PartnersReinhart Partners1.0% of portfolioadded
More on Encompass Health
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #7of 42Hospital and care facility stocks with the highest profit margins
- #9of 25Hospital and care facility stocks with the lowest PE ratio
- #7of 11Hospital and care facility stocks cheapest against their own PE history
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .